Page last updated: 2024-12-06
camphidonium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 26483 |
| CHEMBL ID | 2107688 |
| SCHEMBL ID | 309185 |
| MeSH ID | M0054687 |
Synonyms (33)
| Synonym |
|---|
| trimethidinium methosulfate |
| 1,3,8,8-tetramethyl-3-(3-(trimethylammonio)propyl)-3-azoniabicyclo(3.2.1)octane bis(methyl sulfate) |
| ha 106 |
| s,s'-dimethyl 1,3,8,8-tetramethyl-3-(3-(trimethylammonio)propyl)-3-azoniabicyclo(3.2.1)octane disulphate |
| euprex |
| trimethidinium methosulfate [inn] |
| 3-azoniabicyclo(3.2.1)octane, 1,3,8,8-tetramethyl-3-(3-(trimethylammonio)propyl)-, bis(methyl sulfate) |
| n-(3-trimethylammoniumpropyl)-n-methylcamphidinium bis(methylsulfate) |
| ostensin |
| camphidonium |
| einecs 237-994-2 |
| wy-1395 |
| n-(gamma-trimethylammoniumpropyl)-n-methyl-camphidinium-dimethylsulphate |
| 3-(3-(dimethylamino)propyl)-1,3,8,8-tetramethyl-3-azoniabicyclo(3.2.1)octane methyl sulfate |
| c1o32ij4hs , |
| trimethidinium methosulphate |
| 14149-43-0 |
| unii-c1o32ij4hs |
| trimethidinium methosulfate [inn:nf] |
| wy 1395 |
| tox21_111770 |
| dtxcid6026115 |
| dtxsid8046115 , |
| cas-14149-43-0 |
| trimethidinium methyl sulfate |
| methocamphone methylsulfate |
| CHEMBL2107688 |
| SCHEMBL309185 |
| trimethidinium methosulfate [mi] |
| trimethidinium methosulfate [jan] |
| trimethidinium-methosulfat |
| methyl sulfate;trimethyl-[3-(1,3,8,8-tetramethyl-3-azoniabicyclo[3.2.1]octan-3-yl)propyl]azanium |
| Q27275063 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 21.4697 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 17 (89.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.33) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||